QPatch & Qube users have been busy in Q3, publishing 19 more publications

Here are some select highlights:

  • Ghovanloo et al., PLoS ONE – in a collaboration between Simon Fraser University & Xenon Pharmaceuticals, used the Qube to define the effects of cannabidiol on gramicidin currents, & implications for their antibiotic activities.
  • McMahon et al., Toxins; Wang et al., Membranes – the University of Queensland have two papers. McMahon et al. provide biophysical and pharmacological comparisons of marine snail conotoxins, SxIIIC, SmIIIA & KIIIA, blockers of Nav channels. Wang et al. investigated indole-3-carbinol, a natural product found in Brassica vegetables, their block of T-type calcium channels (Cav3.1-3.3) & roles in cancer anti-proliferation.
  • Watt et al., JPTM – a thorough examination of cardiac ion channel safety pharmacology in hERG, Cav1.2, and Nav1.5 (peak/late), Dr Steve Jenkinson’s team at Pfizer compared GLP manual patch clamp data, Qube APC & hERG binding data, relating data to compound pro-arrhythmia/Torsades de pointes risk modelling.
  • Wade et al., Bioconjugate Chem. – more snakebite antivenom antibody (nanobody) discovery & development in the 4th publication arising from a fruitful collaboration between Prof. Andreas Laustsen’s lab at DTU & Sophion application scientist Dr Kim Boddum.

To see publications, click on the links below:

  • McMahon et al. (2022). µ-Conotoxins Targeting the Human Voltage-Gated Sodium Channel Subtype Nav1.7
  • Davie et al. (2022). A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema.
  • Toti et al. (2022). Structure−Activity Relationship and Neuroprotective Activity of 1,5-Dihydro-2H-naphtho[1,2-b][1,4]diazepine-2,4(3H)-diones as P2X4 Receptor Antagonists.
  • Sengupta et al. (2022). Novel benzoxazinone derivative as potent human neutrophil elastase inhibitor: Potential implications in lung injury.
  • Ghovanloo et al. (2022). Cannabidiol increases gramicidin current in human embryonic kidney cells: An observational study.
  • Caroff et al. (2022). Design, Synthesis, and Pharmacological Evaluation of Benzimidazolo-thiazoles as Potent CXCR3 Antagonists with Therapeutic Potential in Autoimmune Diseases
  • Wang et al. (2022). Diindolylmethane Derivatives: New Selective Blockers for T-Type Calcium Channels.
  • Gu et al. (2022). Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present).
  • Abram et al. (2022). Discovery of (R)‑N‑Benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide [(R)-AS‑1], a Novel Orally Bioavailable EAAT2 Modulator with Druglike Properties and Potent Antiseizure Activity In Vivo.
  • Meyer et al. (2022). Discovery and In Vivo Evaluation of ACT-660602: A Potent and Selective Antagonist of the Chemokine Receptor CXCR3 for Autoimmune Diseases.
  • Watt et al. (2022). Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk – One pharma’s experience and perspective.
  • Jin et al. (2022). Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability.
  • Faria et al. (2022). Environmental levels of carbaryl impair zebrafish larvae behaviour: The potential role of ADRA2B and HTR2B.
  • Wade et al. (2022). Generation of Multivalent Nanobody-Based Proteins with Improved Neutralization of Long α-Neurotoxins from Elapid Snakes. Bioconjugate Chemistry.
  • Zhang et al. (2022). Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for Mycobacterium tuberculosis Treatment.
  • Ma et al. (2022). Use of Solvent Mapping for Characterizing the Binding Site and for Predicting the Inhibition of the Human Ether-á-á-Go-Go-Related K + Channel.
  • Koester et al. (2022). Discovery of Novel Quinoline-Based Proteasome Inhibitors for Human African Trypanosomiasis (HAT).
  • Wang et al. (2022). Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.
  • Feng et al. (2022). Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents.